StreetInsider.com News Articles

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

Mon, 16 Jun 2025 18:40:00 -0400

FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2025.

Financial Highlights

The Company’s third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life sciences tools space, including decreases in government grants, reduced R&D budgets, and tariffs uncertainty, as well as timing of large orders fulfillment.
The Company

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

Mon, 16 Jun 2025 18:40:00 -0400

Financial Highlights

The Company’s third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life sciences tools space, including decreases in government grants, reduced R&D budgets, and tariffs uncertainty, as well as timing of large orders fulfillment.
The Company

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

Mon, 16 Jun 2025 18:40:00 -0400

Financial Highlights

The Company’s third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life sciences tools space, including decreases in government grants, reduced R&D budgets, and tariffs uncertainty, as well as timing of large orders fulfillment.
The Company

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

Mon, 16 Jun 2025 18:40:00 -0400

Financial Highlights

The Company’s third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life sciences tools space, including decreases in government grants, reduced R&D budgets, and tariffs uncertainty, as well as timing of large orders fulfillment.
The Company

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

Mon, 16 Jun 2025 18:40:00 -0400

Financial Highlights

The Company’s third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life sciences tools space, including decreases in government grants, reduced R&D budgets, and tariffs uncertainty, as well as timing of large orders fulfillment.
The Company

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

Mon, 16 Jun 2025 18:40:00 -0400

Financial Highlights

The Company’s third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life sciences tools space, including decreases in government grants, reduced R&D budgets, and tariffs uncertainty, as well as timing of large orders fulfillment.
The Company

Form 8-K ENZO BIOCHEM INC For: Apr 21

Mon, 21 Apr 2025 09:15:00 -0400

si-local-file:///var/storage/secattach/20250421/24660237.html

Form 8-K ENZO BIOCHEM INC For: Apr 21

Mon, 21 Apr 2025 09:15:00 -0400

si-local-file:///var/storage/secattach/20250421/24660237.html

Form 25 ENZO BIOCHEM INC

Mon, 07 Apr 2025 16:15:00 -0400

si-local-file:///var/storage/secattach/20250407/24609382.html

Form 25 ENZO BIOCHEM INC

Mon, 07 Apr 2025 16:15:00 -0400

si-local-file:///var/storage/secattach/20250407/24609382.html

Form 8-K ENZO BIOCHEM INC For: Mar 28

Mon, 31 Mar 2025 16:22:00 -0400

si-local-file:///var/storage/secattach/20250331/24575161.html

Form 8-K ENZO BIOCHEM INC For: Mar 28

Mon, 31 Mar 2025 16:22:00 -0400

si-local-file:///var/storage/secattach/20250331/24575161.html

Enzo Biochem (ENZ) to voluntarily delist from NYSE

Fri, 28 Mar 2025 16:16:29 -0400

(Updated - March 28, 2025 4:16 PM EDT)

Enzo Biochem, Inc. (NYSE: ENZ) today announced its intention to voluntarily delist its common stock from The New York Stock Exchange (“NYSE”) and to have its common stock quoted on the OTCQX Best Market (“OTCQX”).

Enzo provided notice of the voluntary delisting to the NYSE on March 28, 2025 and intends to timely file a notification of removal from listing on Form 25 with the Securities and Exchange Commission (the “SEC”) to effect the delisting. It is anticipated that the delisting will become effective on or about April 17, 2025, with trading on OTCQX

Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX